US Authorizes AstraZeneca COVID Drug for a Few Who Can’t be Vaccinated

U.S. health authorities on Wednesday authorized the use of synthetic antibodies developed by AstraZeneca to prevent COVID-19 infections in people who react badly to vaccines.

It was the first time the Food and Drug Administration has given emergency authorization for such a purely preventative treatment.

The FDA warned the drug Evusheld is “not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended” and can only be authorized for people with weakened immune systems or those who cannot be vaccinated for medical reasons, such a strong allergic reaction.

In those cases, the drug can be administered to people 12 and older.

Evusheld combines two types of synthetic antibodies (tixagevimab and cilgavimab), and is given as two intramuscular injections, one right after the other. These antibodies help the immune system fight off the virus by targeting its spike protein, which allows it to enter cells and infect them.

The FDA said that the treatment “may be effective for pre-exposure prevention for six months.”

It cannot be administered to someone who is already infected with the virus, the FDA said, although AstraZeneca is testing it for such treatment.

Side effects may include an allergic reaction, bleeding from the injection site, headache, and fatigue.

The FDA authorization was based on a clinical trial carried out on unvaccinated people older than 59, or with a chronic disease, or at high risk of infection.

The drug was given to 3,500 people while 1,700 received a placebo. The trial showed that the treatment cut the risk of developing COVID-19 by 77%.

Two cocktails of antibodies, made by Regeneron and Eli Lilly, are currently authorized for prevention of infection in the United States, but only in people who have been exposed to the virus shortly before, or who have a strong chance of being exposed, such as employees of retirement homes or prisons.

In addition to being immunocompromised or unvaccinated, these people must also be at high risk of developing a severe case of the disease.

Source: Voice of America

Nikkiso Clean Energy & Industrial Gases Group Announces a Complete Liquid Hydrogen Bunkering Installation for Unitrove

TEMECULA, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce our participation in the bunkering installation design of a new complete Liquid Hydrogen (LH2) Bunkering installation with Unitrove.

Nikkiso CE&IG and Unitrove are working together to develop solutions for the future, particularly regarding LH2. For this project, the Group provided custom equipment from two of its Functional Units: a sump from its Heat Exchangers unit (Cryoquip) and Cryogenic Pumps unit (ACD).

“We are excited and proud to be part of one of the world’s first liquid hydrogen (LH2) bunkering facility projects and the drive toward more energy-efficient solutions for the Marine market,” according to Ole Jensen, Vice President, Europe, Nikkiso Clean Energy & Industrial Gases Group.

The Bunkering system is being showcased at the United Nations COP26 Environmental Conference in Glasgow, which runs through November 12, 2021. The installation is expected to be completed sometime in 2022.

This will be the first of several expected projects to be delivered in 2022.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Interactive Mirror Allows Retail Customers to Virtually “Try On” Clothing

CALGARY, Alberta, Dec. 07, 2021 (GLOBE NEWSWIRE) — Retail clothing stores of the future will likely have fewer clothes, checkout stations, fitting rooms, employees—and square footage. Instead, you’re likely to see more self-service consoles that allow shoppers to virtually “try on” any garment.

According to NOBAL Technologies, Inc., of Calgary, that future is here right now, with NOBAL’s iMirror product, an interactive mirror that promises to revolutionize the customer experience in the retail realm—much as it’s already doing in hospitality settings.

Explains Royal Bissell, NOBAL’s Director of Innovation, “With a few taps by a customer, the iMirror’s built-in 3D camera takes an accurate full body scan, from which the shopper can create a lifelike avatar of themselves. They can then browse products on the iMirror, and, using their avatar, see exactly how garments will actually look and fit on their body.”

Customers can make purchases directly on the iMirror. NOBAL is reportedly working on a Tap to Pay solution to further facilitate the ecommerce functionality of the iMirror.

According to NOBAL’s Director of Technology, Daniel Maher, unlike other body modelling software whose avatars end up looking cartoonish, “The photo scan taken by the iMirror contains over 200 measurement points, yielding a photo-realistic avatar that’s 94% “measurement-accurate.” When that avatar is clothed in garments with similarly precise measurements, the customer can see exactly how that garment will look—and fit—on them.”

A big plus, reports NOBAL, is that once an avatar is created, a customer can download it to their smart phone, and use it on future visits to any store employing the same technology.

Adds Bissell, “The convenience for the customer is huge: they can instantly see what multiple garments look like on them, minus the time-intensive process of a physical fitting room.”

In the wake of the pandemic, and thanks to innovations like the iMirror, many retailers won’t be bringing back actual fitting rooms. The benefits, note Bissell, are many: “No fitting rooms means dramatically reduced shrinkage. Plus, with no fitting rooms and fewer—or no—checkout counters, a store’s total footprint can be much smaller. Then, there’s the accuracy of our imaging technology, which means better ‘virtual fits’ which, in turn, means far fewer returns.”

Another powerful benefit for retailers, according to NOBAL, is an increased “basket size.” Says Bissell, “With physical fitting rooms, a customer is deciding based on the limited garments available in the store where they’re trying on. In the virtual fitting room, the iMirror can make suggestions based on what the customer has already viewed, as well as the entire store’s inventory or even warehouse items — which are linked to the iMirror.”

NOBAL CEO, Bill Roberts, adds, “Customer satisfaction increases as retailers now have an endless aisle of offerings—even if those garments aren’t physically in the store.” Roberts also notes that their retail customers have reported basket-size jumps of 15-20% by using the iMirror, adding, “They’re discovering their ROI on the product is less than one week.”

According to the company, there may also be a psychological aspect to the proven basket-size increases the iMirror is delivering. Notes Bissell, “We haven’t fully unpacked this idea, but we suspect customers may purchase more items when they’re viewing them virtually, while those trying on actual clothes are more likely to decide not to purchase a given item or items.”

When it comes to the 3D images of clothing that customers’ avatars will “try on,” retailers reportedly can provide their own image library, or NOBAL, using their 3D-imaging technology, can help retailers create those libraries.

Bissell sums up: “We want to replicate the real fitting-room experience and the confidence that comes from physically trying on a garment and knowing that it fits. That’s now possible, given the accuracy of our system. It all adds up to a cost-effective solution with multiple substantive benefits for both customers and retailers.”

For more information on NOBAL’s leading-edge iMirror products, visit www.NOBAL.ca or contact:

Ms. Lindsay Panchyshyn, Director of Marketing
NOBAL Technologies Inc.
403-589-3322 | www.nobal.ca | lpanchyshyn@nobal.ca

Eyenuk Launches EyeArt AI System in South Africa in Collaboration with Discovery Health

A new diabetic retinopathy screening benefit enabled by the EyeArt® AI system is made available by Discovery Health, a global leader in Healthcare and Financial Services

LOS ANGELES, Dec. 07, 2021 (GLOBE NEWSWIRE) — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announces today that Discovery Health launched a new Diabetic Retinopathy Screening Benefit nationwide in South Africa, powered by the cutting-edge EyeArt® AI System helping enable the detection of the onset of diabetic retinopathy as early as possible.

By launching the new Diabetic Retinopathy Screening Benefit, Discovery Health Medical Scheme (DHMS) simplifies access to screening for diabetic retinopathy and introduces cutting-edge AI-driven technology to the process. The Diabetic Retinopathy Screening Benefit follows a simple, three-level process: primary grading by the EyeArt AI System, and if required, secondary grading by an optometrist, and tertiary grading by an ophthalmologist.

“Discovery Health has always focused on incentivising, simplifying and enhancing member access to evidence-based preventative healthcare screening,” says CEO of Discovery Health, Dr. Ryan Noach. “The DHMS Diabetic Retinopathy Screening Benefit is fully aligned to this ethos. It gives members easy access to annual screening, which is conducted using cutting-edge AI technology, followed up by a clear referral process, and supported by scheme benefits requiring no member out-of-pocket payments for primary and secondary grading. Through this benefit, we hope to increase the number of DHMS members who are screened for diabetic retinopathy.”

Frank Cheng, Eyenuk President and CCO, added, “We applaud Discovery Health’s leadership for being the first payor to bring our EyeArt AI system to South Africa. The EyeArt AI System is the most extensively validated and adopted AI system for autonomous diabetic retinopathy detection in real-world settings. It has been cleared by regulatory authorities around the world, including the U.S. Food and Drug Administration (FDA), and is reimbursed by government and private payors in the U.S.”

Dr. Patrick Godard, Chief Commercial Officer at Vertice MedTech, commented, “Diabetic Retinopathy is a growing problem, and Artificial Intelligence (AI) in medical diagnostics signals a new era. Vertice EyeCare is excited to offer the cutting-edge EyeArt AI system in South Africa. The EyeArt AI system provides automated screening in a single office visit by utilising AI algorithms to assess retina images in compliance with international standards. Early identification and treatment can reduce the burden of sight-threatening retinopathy, allowing clinicians to identify patients who require immediate medical treatment without having to worry about mydriasis. Vertice MedTech believes that deploying world-class healthcare innovations such as the EyeArt AI system allows for optimising patient treatment and care.”

About Discovery
Discovery Limited is a South African-founded financial services organisation that operates in the healthcare, life assurance, short-term insurance, savings and investment and wellness markets. Since inception in 1992, Discovery has been guided by a clear core purpose – to make people healthier and to enhance and protect their lives. This has manifested in its globally recognised Vitality Shared-Value insurance model, active in 31 markets with over 20 million members. The model is exported and scaled through the Global Vitality Network, an alliance of some of the largest insurers across key markets including AIA (Asia), Ping An (China), Generali (Europe), Sumitomo (Japan), John Hancock (US), Manulife (Canada), among others. Discovery trades on the Johannesburg Securities Exchange as DSY.
Follow us on Twitter @Discovery_SA

About Vertice MedTech
Vertice MedTech is a collection of South African companies with specialist skill sets, an established track record with defined medical focus areas with many years of practical skill and with experience in several medical specialities, which it offers to identified stakeholders to achieve best medical industry practise and best possible healthcare delivery to African patients. Vertice’s medium-term strategy is to become the leading specialised MedTech group in South Africa and Sub-Saharan Africa. This strategy is being implemented through a buy and build investment thesis augmented by digitisation and support function optimisation. Ethos and the Vertice management team are working together to ensure that Vertice implements operational excellence for each of Vertice’s businesses and has the resources (people, capital, etc) to successfully execute the strategy and establish governance that embeds executive freedom within accountability to the board.

About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. Find Eyenuk online on its websiteTwitterFacebook, and LinkedIn.

About the EyeArt AI System
The EyeArt AI System provides fully autonomous diabetic retinopathy (DR) screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds.

The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to U.S. Food and Drug Administration (FDA) 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

The EyeArt AI System is reimbursable by government and private payors in the U.S. under the newly created Category 1 Current Procedural Terminology (CPT) code 92229.

VIDEO: Learn more about the EyeArt AI System for Autonomous Detection of Diabetic Retinopathy

Discovery Contacts
Karishma Jivan
Reputation Consultant
Healthcare & Sustainability
karishmaj2@discovery.co.za

Nthabiseng Chapeshamano
Press Contact
Senior Reputation Manager
Healthcare & Sustainability
nthabisengc@discovery.co.za

Eyenuk, Inc. Contact
Frank Cheng, President & CCO
frank.cheng@eyenuk.com
+1 818 835 3585